Michael Simons draws on an extensive background in cardiovascular biology in building the Yale Cardiovascular Research Center. A key emphasis has been on the development of innovative platforms for research that combine clinical investigations and basic science.
Dr. Simons has past experience with Beth Israel Deaconess Medical Center at Harvard Medical School as associate professor of medicine. While in this position, he oversaw the establishment of the pioneering Angiogenesis Research Center, which encompassed the efforts of clinical trialists, cardiovascular imagers, and basic scientists. Employing pharmacology and toxicology evaluation, he guided animal studies that were critical in establishing the viability of FGF- and VEGF-based therapies. The studies he oversaw enabled the creation of a Food and Drug Administration submission package and a robust clinical trials infrastructure.